The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 3, 2016, Pages

  Chen, Jiandong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL FATE; CELLS BY BODY ANATOMY; HUMAN; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; ONCOLOGICAL PARAMETERS; PROTEIN PROCESSING; TUMOR INITIATION; ANIMAL; DNA REPAIR; METABOLISM; MOUSE; NEOPLASMS; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; DNA REPAIR; MICE; NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84959461717     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026104     Document Type: Article

References (122)

1. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. 2006. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci 103: 19842–19847.
2. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. 2003. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J 22: 4212–4222.
3. Bergamaschi D, Samuels Y, O’Neil NJ, Trigiante G, Crook T, Hsieh JK, O’Connor DJ, Zhong S, Campargue I, Tomlinson ML, et al. 2003. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33: 162–167.
4. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, et al. 2006. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133–1141.
5. Bonasio R, Tu S, Reinberg D. 2010. Molecular signals of epigenetic states. Science 330: 612–616.
6. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al. 2011. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145: 571–583.
7. Brodsky MH, Weinert BT, Tsang G, Rong YS, McGinnis NM, Golic KG, Rio DC, Rubin GM. 2004. Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol 24: 1219–1231.
8. Brown JP, Wei W, Sedivy JM. 1997. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277: 831–834.
9. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–557.
10. Cain C, Miller S, Ahn J, Prives C. 2000. The N terminus of p53 regulates its dissociation fromDNA. J Biol Chem 275: 39944–39953.
11. Campisi J. 2005. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120: 513–522.
12. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. 2005. Activation of p53 byMDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65: 1918–1924.
13. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB. 1999a. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59: 3761–3767.
14. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, Roninson IB. 1999b. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18: 4808–4818.
15. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745–752.
16. Checler F, Alves da Costa C. 2014. p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther 142: 99–113.
17. Chen J. 2012. The roles of MDM2 and MDMX phosphorylation in stress signaling to p53. Genes Cancer 3: 274–282.
18. Chen X, Ko LJ, Jayaraman L, Prives C. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438–2451.
19. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, et al. 2011. Control of the senescence-associated secretory phenotype by NF-kB promotes senescence and enhances chemosensitivity. Genes Dev 25: 2125–2136.
20. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. 2005. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309: 1732–1735.
21. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849–852.
22. Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D’Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A. 2012. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 8: e1002797.
23. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ. 1995. A p53-dependent mouse spindle checkpoint. Science 267: 1353–1356.
24. Croxton R, Ma Y, Song L, Haura EB, Cress WD. 2002. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 21: 1359–1369.
25. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. 2009. Rapamycin decelerates cellular senescence. Cell Cycle 8: 1888–1895.
26. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. 2010. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci 107: 9660–9664.
27. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675–684.
28. Derry WB, Putzke AP, Rothman JH. 2001. Caenorhabditis elegans p53: Role in apoptosis, meiosis, and stress resistance. Science 294: 591–595.
29. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. 2007. Nutlin-3 inhibits the NFkB pathway in a p53-dependent manner: Implications in lung cancer therapy. Cell Cycle 6: 2178–2185.
30. Du W, Wu J, Walsh EM, Zhang Y, Chen CY, Xiao ZX. 2009. Nutlin-3 affects expression and function of retinoblastoma protein: Role of retinoblastoma protein in cellular response to nutlin-3. J Biol Chem 284: 26315–26321.
31. Duensing A, Duensing S. 2005. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 331: 694–700.
32. Dunker AK, Silman I, Uversky VN, Sussman JL. 2008. Function and structure of inherently disordered proteins. Curr Opin Struct Biol 18: 756–764.
33. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993.WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
34. Feng Z, Zhang H, Levine AJ, Jin S. 2005. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci 102: 8204–8209.
35. Finlay CA, Hinds PW, Levine AJ. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083–1093.
36. Friedler A, Veprintsev DB, Rutherford T, von Glos KI, Fersht AR. 2005. Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J Biol Chem 280: 8051–8059.
37. Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegue E, Evan GI. 2011. Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev 25: 1746–1757.
38. Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, Yue W, Yu J, Zhang L, Onciu M, et al. 2008. Selection againstPUMAgene expression inMyc-driven B-cell lymphomagenesis. Mol Cell Biol 28: 5391–5402.
39. Gatz SA, Wiesmuller L. 2006. p53 in recombination and repair. Cell Death Differ 13: 1003–1016.
40. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, et al. 2012. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18: 1239–1247.
41. Gorina S, Pavletich NP. 1996. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001–1005.
42. Greiss S, Schumacher B, Grandien K, Rothblatt J, Gartner A. 2008. Transcriptional profiling in C. elegans suggests DNA damage dependent apoptosis as an ancient function of the p53 family. BMC Genomics 9: 334.
43. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. 2006. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26: 192–198.
44. Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, et al. 2013. The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes Dev 27: 1868–1885.
45. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
46. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8: 2457–2467.
47. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447: 1130–1134.
48. Hershko T, Ginsberg D. 2004. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279: 8627–8634.
49. Horvath MM, Wang X, Resnick MA, Bell DA. 2007. Divergent evolution of human p53 binding sites: Cell cycle versus apoptosis. PLoS Genet 3: e127.
50. Huang B, Deo D, Xia M, Vassilev LT. 2009. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 7: 1497–1509.
51. Jain AK, Barton MC. 2012. Unmet expectations: miR-34 plays no role in p53-mediated tumor suppression in vivo. PLoS Genet 8: e1002859.
52. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, et al. 2003. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4: 321–328.
53. Kaeser MD, Iggo RD. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53DNAbinding activity in vivo. ProcNatlAcad Sci 99: 95–100.
54. Khoo KH, Verma CS, Lane DP. 2014. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov 13: 217–236.
55. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV. 1997. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391–1400.
56. Kranz D, Dobbelstein M. 2006. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res 66: 10274–10280.
57. Lanni JS, Jacks T. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18: 1055–1064.
58. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61–66.
59. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. 2004. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443–450.
60. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. 2012. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149: 1269–1283.
61. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. 2004. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36: 63–68.
62. Luo Y, Hurwitz J, Massague J. 1995. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375: 159–161.
63. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A,Walsh FS, Wright EG, Balmain A, Lane DP, et al. 1996. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13: 2575–2587.
64. Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, Lu X, Crook T, Del Sal G. 2007. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 14: 912–920.
65. Mao JH, Wu D, Kim IJ, Kang HC, Wei G, Climent J, Kumar A, Pelorosso FG, DelRosario R, Huang EJ, et al. 2012. Hipk2 cooperates with p53 to suppress g-ray radiationinduced mouse thymic lymphoma. Oncogene 31: 1176–1180.
66. Marchenko ND, Zaika A, Moll UM. 2000. Death signalinduced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275: 16202–16212.
67. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. 2001. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 61: 6234–6238.
68. Martinez J, Georgoff I, Levine AJ. 1991. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5: 151–159.
69. Michalak EM, Villunger A, Adams JM, Strasser A. 2008. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15: 1019–1029.
70. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577–590.
71. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703–716.
72. Oberst A, Bender C, Green DR. 2008. Living with death: The evolution of the mitochondrial pathway of apoptosis in animals. Cell Death Differ 15: 1139–1146.
73. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, et al. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862.
74. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagawara A, Kizaki H. 2008. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283: 3979–3987.
75. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92–95.
76. Perfettini JL, Castedo M, Nardacci R, Ciccosanti F, Boya P, Roumier T, Larochette N, Piacentini M, Kroemer G. 2005. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med 201: 279–289.
77. Petros AM, Gunasekera A, Xu N, Olejniczak ET, Fesik SW. 2004. Defining the p53 DNA-binding domain/Bcl-xLbinding interface using NMR. FEBS Lett 559: 171–174.
78. Pietsch EC, Perchiniak E, Canutescu AA, Wang G, Dunbrack RL, Murphy ME. 2008. Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem 283: 21294–21304.
79. Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. 2010. p53-dependent senescence delays Em-myc-induced B-cell lymphomagenesis. Oncogene 29: 1260–1269.
80. Puca R, Nardinocchi L, Givol D, D’Orazi G. 2010. Regulation of p53 activity by HIPK2: Molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 29: 4378–4387.
81. Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. 2012. p53 dynamics control cell fate. Science 336: 1440–1444.
82. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. 2002. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 21: 7901–7911.
83. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, et al. 2012. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-ofmechanism study. Lancet Oncol 13: 1133–1140.
84. Rigatti MJ, Verma R, Belinsky GS, Rosenberg DW, Giardina C. 2012. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol Carcinog 51: 363–378.
85. Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402–412.
86. Ringshausen I, O’Shea CC, Finch AJ, Swigart LB, Evan GI. 2006. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10: 501–514.
87. Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D, Coppe JP, Campeau E, Beausejour CM, Kim SH, et al. 2011. DNA-SCARS: Distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci 124: 68–81.
88. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. 1996. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15: 827–838.
89. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. 2005. The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306–1313.
90. Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781–794.
91. Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, Vogiatzi F, Leich E, Samans B, Eilers M, et al. 2010. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 38: 356–368.
92. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335–346.
93. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, Allday MJ, Xiao ZX. 2005. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699–708.
94. Sot B, Freund SM, Fersht AR. 2007. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J Biol Chem 282: 29193–29200.
95. St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, Dastidar J, DaCosta A, Mattia M, Manfredi JJ. 2004. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: One involves direct binding to the cdc25C promoter. Mol Cell 16: 725–736.
96. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. 2012. ATM and MET kinases are synthetic lethalwith nongenotoxic activation of p53. Nat Chem Biol 8: 646–654.
97. Sutcliffe JE, Brehm A. 2004. Of flies and men; p53, a tumour suppressor. FEBS Lett 567: 86–91.
98. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB. 2006. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841–851.
99. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703–711.
100. Szak ST, Mays D, Pietenpol JA. 2001. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 21: 3375–3386.
101. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. 2007. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response toDNA damage. Mol Cell 25: 725–738.
102. Tait SW, Green DR. 2010. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621–632.
103. Tang Y, Luo J, Zhang W, Gu W. 2006. Tip60-dependent acetylation of p53 modulates the decision between cellcycle arrest and apoptosis. Mol Cell 24: 827–839.
104. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. 2008. Acetylation is indispensable for p53 activation. Cell 133: 612–626.
105. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. 2007. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586–1593.
106. Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt B, Pagenstecher A, Rosenwald A, Elsasser HP, Stiewe T. 2013. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep 3: 1512–1525.
107. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C, Pan H, Kessler H, Pancoska P, Moll UM. 2006. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 281: 8600–8606.
108. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, et al. 2006. Small-moleculeMDM2antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci 103: 1888–1893.
109. Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. 2013. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 3: 1339–1345.
110. Valentin-Vega YA, Box N, Terzian T, Lozano G. 2009.Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation 77: 442–449.
111. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. 2012. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149: 1536–1548.
112. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661–665.
113. Vousden KH, Prives C. 2009. Blinded by the light: The growing complexity of p53. Cell 137: 413–431.
114. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintas-Cardama A, Bankson JA, El-Naggar AK, Lozano G. 2011. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121: 893–904.
115. Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR. 2005. Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 348: 589–596.
116. Wu X, Levine AJ. 1994. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci 91: 3602–3606.
117. Xu D, Woodfield SE, Lee TV, Fan Y, Antonio C, Bergmann A. 2009. Genetic control of programmed cell death (apoptosis) in Drosophila. Fly 3: 78–90.
118. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656–660.
119. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345–347.
120. Yoshida K, Liu H, Miki Y. 2006. Protein kinase C d regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 281: 5734–5740.
121. Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. 2014. Tissue-specific and agedependent effects of global Mdm2 loss. J Pathol 233: 380–391.
122. Zheng H, Chen L, Pledger WJ, Fang J, Chen J. 2013. p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression. Oncogene 33: 734–744.